PICO
Structured summariesStructured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
Do Ketone Bodies Affect the Heart Differently in Type 1 Diabetes?
A randomized crossover trial found the cardiac output response to 3-hydroxybutyrate was blunted by roughly 80% in type 1 diabetes, with no gain in systolic function and reduced ventricular work efficiency. PICO summary and expert commentary.
Lotiglipron for Type 2 Diabetes and Obesity: A Phase 2 Trial Stopped for Liver Safety
An oral GLP-1 receptor agonist lowered HbA1c and body weight in phase 2 but was halted early after transaminase elevations ended its development. PICO summary and expert commentary.
Do Carbohydrate and Protein Types Affect Blood Sugar in Type 1 Diabetes?
Two small crossover trials in adults with type 1 diabetes found neither protein source nor carbohydrate glycaemic index significantly altered postprandial glucose. PICO summary and expert commentary.
Do Calorie-Restriction Gut Hormone Shifts Predict Weight Regain?
A 253-adult randomized trial found that 25% calorie restriction produced consistent enteropancreatic hormone shifts across diet patterns, and that larger shifts were associated with more weight regain afterwards. PICO summary and expert commentary.
Liraglutide 3.0 mg for Weight Recurrence After Roux-en-Y Gastric Bypass: An RCT
A 56-week randomized, double-blind, placebo-controlled trial of liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. PICO summary and expert commentary.
Does a Low-Glycemic Carbohydrate Product Improve Maternal Glycemia in Obese Pregnant Women?
A manufacturer-sponsored randomized trial of a low-glycemic-index/slow-digesting carbohydrate product in obese pregnant women found no effect on the primary glycemic outcomes. PICO summary and expert commentary.
Does Exenatide Affect Heart Failure Outcomes by Ejection Fraction in Type 2 Diabetes?
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
BI 1820237 (NPY2R Agonist): Phase I Safety in Overweight Men
A first-in-human phase I trial of the NPY2 receptor agonist BI 1820237, alone or with low-dose liraglutide, in 95 men with overweight or obesity, reporting safety, tolerability, and additive effects on gastric emptying. PICO summary and expert commentary.
Does Baseline IL-1β Predict Liver Improvement After Weight Loss?
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.